How the answers frame Merck
This snapshot, taken 2026-09-28, covers 25 answers from ChatGPT, Claude, Gemini, Perplexity and Grok to five category questions that never named a brand. Merck was named in 13 of them. Grok named it in four of its five answers, ChatGPT and Gemini in three each, Perplexity in two and Claude in one. Pfizer (15) was named in more answers. Johnson & Johnson matched Merck at 13.
The credits attached to Merck were mixed. Four answers named it without a substantive reason. Four tied it to safety and compliance, mostly through litigation. Three tied it to price and value, and one to workplace reputation. Gemini's litigation answer said Merck was "notable for its substantial settlement regarding the painkiller Vioxx". ChatGPT's litigation answer also pointed to Vioxx. Grok's version called Vioxx "smaller in aggregate here".
On pricing, Gemini said Merck is "regularly involved in pricing debates" and named its diabetes and cancer treatments. Grok listed Merck among large companies criticized over launch prices and U.S.-international price gaps on drugs including Keytruda. On the trust question, Gemini credited Merck & Co. only for employer reputation, citing Glassdoor. ChatGPT's answer to the same question said no single universal list of trusted pharma companies exists.
Some answers appear to blur Merck & Co. with the German company Merck KGaA. ChatGPT's patient-access answer listed Merck KGaA in the 2024 Access to Medicine Index. Grok referred to "Merck (Germany)" in a trust ranking. Perplexity's pricing answer named "Merck Group" at the bottom of a PatientView-based ranking. The dataset tied all three to the Merck brand.
…not necessarily the most sued by count, but one of the biggest pharma litigation names historically, especially because of Vioxx and other large settlements…
What the press is saying
PeakMetrics' news index shows 20,326 mentions of Merck over the last 30 days, 1,897 of them with the brand in the headline. That is the highest count in the peer set here, ahead of Pfizer (18,663), Eli Lilly (19,280) and Johnson & Johnson (15,149).
The sampled headlines are about a positive EU CHMP opinion for Keytruda plus Padcev in bladder cancer, and about Bio-Techne shareholders approving an acquisition by Merck KGaA. Two are stock-comparison pieces saying Merck & Co. outperformed Johnson & Johnson and Bristol-Myers Squibb. One is a market report that lists Merck KGaA among equipment companies. The same name confusion appears in the press stream.
A separate PatientView-based ranking listed **Merck Group**, **Teva**, and **Allergan** at the bottom.
The gap
The press story is about pipeline, deals and market performance. The answer story is about reputation questions: who is trusted, who is criticized on price, who has faced lawsuits. Keytruda appeared in one answer, as a pricing example, and the recent regulatory news did not appear in any of them.
Press volume did not translate into a lead role. Merck had the most news mentions in its peer set but was named in fewer answers than Pfizer. Eli Lilly had nearly the same news volume and was named in 6 of 25 answers. In these answers, Merck's visibility rested on historical litigation and pricing debates more than on current coverage.
What to watch
A comms team can check which questions pull Merck in and which reasons the assistants attach. In this snapshot the reasons were litigation history, pricing criticism and, once, employer reputation. Trust and patient-access answers tended to lead with other companies.
Entity ambiguity is a practical issue. When answers fold Merck KGaA or "Merck Group" into Merck's results, reputation attributions can travel between two companies. This is a single snapshot from two assistants' worth of sampling logic and five providers, so repeat the benchmark questions before treating any pattern as stable.